3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
9
Pancreatic Neoplasms
7
Glioblastoma
7
Carcinoma, Non-Small-Cell Lung
5
Breast Neoplasms
4
Triple Negative Breast Neoplasms
3
Ovarian Neoplasms
3
Neoplasms
3
Lung Neoplasms
3
Colonic Neoplasms
3
Urinary Bladder Neoplasms
2
Prostatic Neoplasms
2
Osteosarcoma
2
Myelodysplastic Syndromes
2
Lymphoma, Follicular
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Myeloid, Acute
2
Glioma
2
Fibrolamellar hepatocellular carcinoma
2
Fallopian Tube Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Merkel Cell
2
Carcinoma, Hepatocellular
2
Carcinoma
2
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Urologic Neoplasms
1
Thrombocythemia, Essential
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Interventions
Carboplatin
19
Paclitaxel
18
Fluorouracil
16
Cisplatin
16
pembrolizumab
15
Radiotherapy
14
Oxaliplatin
12
Irinotecan
12
Capecitabine
12
Cyclophosphamide
10
Radiation
8
Leucovorin
8
Docetaxel
8
fludarabine
6
Taxes
6
Gemcitabine
6
Trastuzumab
5
fludarabine phosphate
4
aldesleukin
4
LY6K protein, human
4
Fluorodeoxyglucose F18
4
Erlotinib Hydrochloride
4
Bevacizumab
4
spartalizumab
3
Surgical Procedures, Operative
3
S 1 (combination)
3
Pemetrexed
3
Nivolumab
3
Drug Therapy
3
zimberelimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Esophageal Neoplasms
×
poly ICLC
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled